Longevity market will grow from $5 trillion to $8 trillion in next four years.

Longevity market will grow from $5 trillion to $8 trillion in next four years. | the market uh of longevity uh and this is going beyond just retrospective reactive health care to prospective um personalized healthcare is going from 5 trillion to 8 trillion in the next four years.

Watch events: Life Biosciences ER-100 Phase 1 first readout (likely late 2026/early 2027)

the market uh of longevity uh and this is going beyond just retrospective reactive health care to prospective um personalized healthcare is going from 5 trillion to 8 trillion in the next four years.

Beneficiaries (23)

Adverse (5)

{
  "nia": false,
  "qty": "$5T to $8T",
  "url": "https://www.youtube.com/watch?v=T8X6kp-pcKs",
  "mode": "FORECAST",
  "role": "Host",
  "context": "the market uh of longevity uh and this is going beyond just retrospective reactive health care to prospective um personalized healthcare is going from 5 trillion to 8 trillion in the next four years.",
  "to_year": 2030,
  "verbatim": "the market uh of longevity uh and this is going beyond just retrospective reactive health care to prospective um personalized healthcare is going from 5 trillion to 8 trillion in the next four years.",
  "conv_cues": "is going",
  "direction": "NUMERIC_TARGET",
  "from_year": 2030,
  "timeframe": "2030",
  "conv_level": "HIGH",
  "milestones": [
    {
      "kind": "llm_pre_event",
      "label": "Narrow longevity-biotech market exceeds $30B in 2025",
      "notes": "HIT — narrow market is ~$30B per analysts. Diamandis's $5T number is the broader healthspan/economic-value framing per LBS/Oxford/Harvard 'value of one healthy year' research.",
      "source": "Mordor Intelligence — Longevity Market Share, Size & Growth Outlook to 2031",
      "status": "hit",
      "weight": 0.4,
      "ordinal": -8,
      "source_id": null,
      "confidence": 0.95,
      "source_url": "https://www.mordorintelligence.com/industry-reports/longevity-market",
      "expected_date": "2025-12-31",
      "observed_date": "2025-12-31",
      "research_origin": "deep_research",
      "measurement_criterion": "Multiple analyst reports (Mordor, SNS Insider, MarketResearchFuture) converge on narrow longevity biotech market valuation of $25-30B in 2025."
    },
    {
      "kind": "llm_pre_event",
      "label": "Healthspan economic value studies converge on $38T-$300T figures",
      "notes": "These studies are the underlying sources for Diamandis's '$5T to $8T' number; they need to hold up over the 4-year window.",
      "source": "Oliver Wyman — How The Longevity Revolution Is Changing Life As We Know It",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -7,
      "source_id": null,
      "confidence": 0.7,
      "source_url": "https://www.oliverwyman.com/our-expertise/insights/2025/apr/how-governments-harness-growth-in-longevity-market.html",
      "expected_date": "2026-07-02",
      "research_origin": "deep_research",
      "expected_date_range": {
        "to": "2027-12-31",
        "from": "2025-01-01"
      },
      "measurement_criterion": "Peer-reviewed economic studies (LBS / Oxford / Harvard / NBER) confirm or update the $38T-per-healthy-year and $300T-for-10-years global economic value estimates that underpin Diamandis's framing."
    },
    {
      "kind": "llm_pre_event",
      "label": "Diamandis Abundance360 Longevity Trip 2026 confirms market thesis",
      "notes": "Direct re-confirmation of the speaker's framing. Note: Diamandis's $5T-$8T figure includes broader healthspan economy, not narrow biotech revenue.",
      "source": "Abundance Longevity Trip 2026",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -6,
      "source_id": null,
      "confidence": 0.85,
      "source_url": "https://longevity.abundance360.com/",
      "expected_date": "2026-10-31",
      "research_origin": "deep_research",
      "measurement_criterion": "Peter Diamandis personally hosts October 2026 Abundance Longevity 5-day immersion, reaffirming his $5T to $8T longevity market thesis to attendees."
    },
    {
      "kind": "llm_pre_event",
      "label": "Major pharma cap-ex reallocation toward longevity / aging programs",
      "notes": "Required to validate that the 'market growth' is real capital deployment, not just analyst enthusiasm.",
      "source": "Anticipated — pharma 10-K disclosures, R&D Day presentations",
      "status": "pending",
      "weight": 0.4,
      "ordinal": -5,
      "source_id": null,
      "confidence": 0.55,
      "expected_date": "2028-03-16",
      "research_origin": "training",
      "expected_date_range": {
      
... (truncated)